0022 GMT - The idea that fitness wearables or weight-loss drugs could create a step-change in demand for ResMed is too underdeveloped to incorporate into earnings forecasts, Wilsons analyst Shane Storey says. Cutting his recommendation on the breath-tech provider to market weight from overweight, Storey concedes that the growing use of GLP-1 drugs is a potential tailwind to the sleep industry, but thinks its impact can't yet be predicted. He writes in a note that ResMed's manufacturing and procurement initiatives, and scale benefits, will materialize in fiscal 2026 and fiscal 2027. Wilsons lifts its target price by 1.5% to A$42.82. Shares are down 3.2% at A$38.90. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 02, 2025 19:22 ET (00:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。